Phase 2 Oesophageal Cancer Trial, Recruiting NCT06354140 Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 2 Oesophageal Cancer Trial, Recruiting

NCT06354140
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old (any gender)
  • You have been diagnosed with squamous cell carcinoma (a type of cancer) of the esophagus (food pipe) and received immunotherapy combined with chemotherapy before surgery (and radiation therapy was not part of your treatment plan)
  • After surgery, your pathology results showed cancer still present at the original tumor site and/or in nearby lymph nodes, at a specific stage (confirm with trial site)
  • Your surgery was intended to completely remove the cancer (a "radical resection")
  • You are generally well enough to carry out light activity and care for yourself, with little or no limitation on daily activities (ECOG score of 0 or 1 — confirm with trial site)
  • Scans or tests done before starting post-surgery treatment show no signs that the cancer has come back or spread to other parts of the body
  • Your organ functions (such as heart, liver, and kidneys) are healthy enough to receive chemotherapy and immunotherapy
  • You are willing and able to understand and sign a consent form to take part in the study

Who may not be able to join:

  • You have been diagnosed with another type of cancer within the past 5 years (though some fully cured cancers, such as certain skin cancers, early cervical cancer, or early prostate cancer, may still be allowed — confirm with trial site)
  • You have a history of interstitial lung disease (scarring or inflammation of the lungs), or have had lung inflammation in the past that needed steroid treatment
  • You have been taking steroid medicines (such as prednisone above a certain dose) or other drugs that suppress the immune system within the 2 weeks before joining the trial
  • You have had a severe allergic reaction to chemotherapy drugs (specifically fluorouracil) or to any monoclonal antibody (a type of immunotherapy drug)
  • You have an autoimmune disease that is currently active (a condition where the immune system attacks the body's own tissues)
  • You currently have active hepatitis (liver infection/inflammation)
  • The trial doctors decide there is another reason that makes it unsuitable for you to participate (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 13527323568

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Registry
ClinicalTrials.gov
Start date
7 May 2024
Est. completion
30 May 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

1-year DFS rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov